
ProKidney Posts $35.6M Q3 Loss as Trials Ramp
The Winston-Salem biopharmaceutical company reported a third-quarter loss of $35.6 million as spending on clinical studies grew.

The Winston-Salem biopharmaceutical company reported a third-quarter loss of $35.6 million as spending on clinical studies grew.